Trial Profile
Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Peginterferon alfa-2a
- Indications Liver cancer
- Focus Therapeutic Use
- 10 Aug 2013 Status changed from not stated to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 03 Jun 2011 New trial record